FDA Clearance Tracker · P240028-S001
WiSE® (Wireless Stimulation of the Endocardium Technology) CRT System
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jun 18, 2025
Approved
Time to decision
30 days
Received May 19, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240028-S001
- Device name
- WiSE® (Wireless Stimulation of the Endocardium Technology) CRT System
- Applicant
- EBR Systems, Inc.
- Applicant location
- Sunnyvale, CA
- Received
- May 19, 2025
- Decided
- Jun 18, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240028
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
approval of the The WiSE-UP Registry (The WiSE System Utilization & Performance Registry) post-approval study protocol
Source documents
Other decisions for EBR Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240028 · Decided Apr 11, 2025 · 225 days after receipt
Device type: Leadless Cardiac Resynchronization Therapy (CRT) (SEG) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.